Urol. praxi, 2014; 15(3): 120-122
Chemotherapy in the treatment of castration-resistant prostate cancer
- Onkologicko-chirurgické oddělení FN u sv. Anny, Brno
Chemotherapy in the treatment of castration-resistant prostate cancer is used in the first- and second-line therapy with a benefit of
prolonged survival and improved quality of life. Docetaxel is a drug standardly used in the first-line therapy. Cabazitaxel is the first
cytostatic drug to have been shown to extend survival in patients treated in the second line after previous treatment with docetaxel.
Vinorelbine, particularly due to its good tolerance, represents an option for patients with contraindications to taxane administration.
Keywords: chemotherapy, docetaxel, cabazitaxel, retreatment with docetaxel, vinorelbine
Published: July 1, 2014 Show citation
References
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. N Engl J Med 2004; 351: 1502-1512.
Go to original source... 
Go to PubMed... - De Bono JS, Oudard S, Ozguroglu M, at al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel teratment: a randomised open-label trial. Lancet 2010; 376: 1147-1154. Go to original source... Go to PubMed...
- Bahl A, Oudard S, Tombal S, et al. Impact of cabazitaxel on 2-year survival and palliation of tumor-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann of Oncol 2013, 00:1-7 doi: 10.1093/annonc/mdt194. Go to original source... Go to PubMed...
- Ansari J, Hussain SA, et al. Role of Second-Line Systemic Treatment porst-Docetaxel in Metastatic Castrate Resistant Prostate Cancer-Current Strategies and Future Directions. Anti-Cancer Agents in Medicinal Chemoistry, 2011; 11: 296-306. Go to original source... Go to PubMed...
- Ross RW, Beer TM, et al. A phase 2 study of carboplatin plus docetaxel and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate cancer who are refractory to docetaxel. Cancer, 2008; 112(3): 521-526. Go to original source... Go to PubMed...
- Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial. J Clin Oncol. 2009; 27(32): 5431-5438. Go to original source... Go to PubMed...
- Zamdino MG, Verri E, et al. Vinorelbine-based Chemotherapy in Hormone-refractory Prostate Cancer. Anticancer Res. 2006; 26: 2375-2380.
- Rodriguez Garzotto A, Sepulveda J, Cortijo A, et al. Oral vinorelbine as a fixed-weekly schedule in taxanes-refractory advanced HRPC: A single institution experience. J Clin Oncol, 2009; abstr 16084. Go to original source...
- Matoušková M, Katolická J, Hanuš M, Divišová K, Rotnáglová S, Rovný A, Filipenský P. Chemoterapie II. linie CRCP-vinorelbin + hydrokortizon - prospektivní multicentrická studie. Česká urologie. 2012; 16(1), 75.